Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202890 · ClinicalTrials.gov registry record · Phase 1
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01202890: Clinical Trial Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
NCT01202890 is a Phase 1 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01202890, a Phase 1 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will test the feasibility of combining 3 drugs, Revlimid with Doxil and Bevacizumab,and gather preliminary data on the potential activity of the combination in patients with platinum resistant/refractory ovarian cancer.
Interventions
- DRUG Lenalidomide, Liposomal Doxorubicin, Bevacizumab
- DRUG Revlimid, Doxil, Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Why NCT01202890 stopped before completion
NCT01202890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide, Liposomal Doxorubicin, Bevacizumab is the first listed.
NCT01202890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01202890 about?
NCT01202890 is a clinical study titled "Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer". This study will test the feasibility of combining 3 drugs, Revlimid with Doxil and Bevacizumab,and gather preliminary data on the potential activity of the combination in patients with platinum resistant/refractory ovarian cancer.
What is the current status of trial NCT01202890?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2010-09. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01202890?
The interventions under investigation include: Lenalidomide, Liposomal Doxorubicin, Bevacizumab (DRUG), Revlimid, Doxil, Avastin (DRUG).
Who is sponsoring clinical trial NCT01202890?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01202890's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia